It will be interesting to see if this translates into lower risk of hard outcomes, like heart attacks and deaths.
Previous trials of CETP inhibitors have failed for CVD, but obicetrapib looks more promising.
Steve Kaplan's shared post reports a study of the CETP inhibitor obicetrapib in high-risk patients already on statins, with meaningful reductions in LDL and other atherogenic lipids and higher HDL. Louis notes earlier CETP inhibitors failed on CVD outcomes and that hard-event results remain to be seen.
It will be interesting to see if this translates into lower risk of hard outcomes, like heart attacks and deaths.
Previous trials of CETP inhibitors have failed for CVD, but obicetrapib looks more promising.
In a just-released study, researchers evaluated the drug Obicetrapib — a potent inhibitor of the cholesteryl ester transfer protein (CETP) — in patients at high cardiovascular risk who were already on statin therapy. They found that Obicetrapib produced meaningful reductions in LDL-cholesterol and other atherogenic lipids, while simultaneously raising HDL-cholesterol.